These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20345729)

  • 21. Controversy of proton pump inhibitor and clopidogrel interaction: a review.
    Tan HJ
    J Dig Dis; 2010 Dec; 11(6):334-42. PubMed ID: 21091895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
    Fernando H; Bassler N; Habersberger J; Sheffield LJ; Sharma R; Dart AM; Peter KH; Shaw JA
    J Thromb Haemost; 2011 Aug; 9(8):1582-9. PubMed ID: 21696537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.
    Guérin A; Mody R; Carter V; Ayas C; Patel H; Lasch K; Wu E
    PLoS One; 2016; 11(1):e0145504. PubMed ID: 26727382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Effects of Pantoprazole on Platelet Aggregation in Blood Samples From Clopidogrel and Aspirin-treated Patients.
    Karlsson E; Holm M; van der Linden JA
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):191-5. PubMed ID: 27110745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.
    Tsukahara K; Kimura K; Morita S; Ebina T; Kosuge M; Hibi K; Iwahashi N; Endo M; Maejima N; Sugano T; Umemura S
    J Cardiol; 2011 May; 57(3):275-82. PubMed ID: 21371863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome".
    Potter BJ; Le Lorier J
    Circulation; 2010 Aug; 122(5):e414; author reply e415. PubMed ID: 20679578
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
    Lettino M
    Eur J Intern Med; 2010 Dec; 21(6):484-9. PubMed ID: 21111931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
    J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clopidogrel-proton pump inhibitor interaction: a primer for clinicians.
    Allen C; Dunn SP; Macaulay TE; Mukherjee D
    Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):66-72. PubMed ID: 20041840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Proton pump inhibitors and clopidogrel: a hazardous association?].
    Szymezak J; Gaussem P
    Rev Med Interne; 2013 Feb; 34(2):99-104. PubMed ID: 23200799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.
    Harmsze AM; van Werkum JW; Souverein PC; Breet NJ; Bouman HJ; Hackeng CM; Ruven HJ; ten Berg JM; Klungel OH; de Boer A; Deneer VH
    J Thromb Haemost; 2011 Oct; 9(10):1892-901. PubMed ID: 21854540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-dose clopidogrel in patients undergoing PCI for ACS.
    Vassiliou V
    Lancet; 2011 Jan; 377(9762):297; author reply 298. PubMed ID: 21256377
    [No Abstract]   [Full Text] [Related]  

  • 36. The safety of proton pump inhibitors and clopidogrel in patients after stroke.
    Juurlink DN; Gomes T; Mamdani MM; Gladstone DJ; Kapral MK
    Stroke; 2011 Jan; 42(1):128-32. PubMed ID: 21164123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
    Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of pharmacotherapeutic warnings on the prescription of clopidogrel and proton pump inhibitors in hospitalised patients].
    Sánchez Ruiz-Gordoa M; Tenías Burillo JM; Ruiz Martín de la Torre R; Valenzuela Gámez JC
    Farm Hosp; 2012; 36(4):250-5. PubMed ID: 22118768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
    Cuisset T; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Brissy O; Morange PE; Alessi MC; Bonnet JL
    J Am Coll Cardiol; 2009 Sep; 54(13):1149-53. PubMed ID: 19761935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.